WEDGES: A prospective, multi-center randomized trial for the evaluation of coronary lesion preparation: an assessment of a new scoring balloon by quantitative stent enhanced visualization
Sittard, the Netherlands, November 13, 2020 – Brosmed Medical, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Belgium have been enrolled in the Wedges study, a multi-center randomized trial for the evaluation of coronary lesion preparation with enhanced dilatation for the good expansion of stent: assessment of a new scoring balloon by quantitative enhanced visualization.
The Wedge is a scoring balloon dilatation catheter that comes in a non-compliant as well as a semi-compliant version for safe and controlled lesion preparation.
Dr. Stephane Carlier, head of the Cardiology Department at CHU Ambroise Pare & UMONS – Mons, Belgium, where the first patients in Belgium will be treated, said, Brosmed Medical´s new scoring catheter technology allows physicians to gently modify calcified plaque and enables coronary revascularization for patients with calcified arteries in a more controlled manner. The introduction of the Wedge in Belgium greatly improves the treatment options for my patients suffering from coronary artery disease, or CAD. About Brosmed Medical
BrosMed is a high-value medical device manufacturer specializing in the design, production, and sales of vascular interventional medical devices. At present, BrosMed global product line covers cardiovascular interventions, peripheral vascular interventions and a full set of interventional accessories.
Exhibitor Data Sheet